Peptides · Peptide comparison
Intermedin (Adrenomedullin-2) vs Thymosin Beta-4
A powerful peptide hormone that protects your heart and blood vessels while managing stress and inflammation naturally.
The body's natural healing peptide that accelerates tissue repair and reduces inflammation
- Healing & Recovery
- Healing & Recovery
At a glance
Quick comparison
Efficacy
Benefit ratings
Cardiovascular Health & Protection
Stress & Anxiety Management
Anti-Inflammatory & Antioxidant Support
Wound Healing
Inflammation Reduction
Tissue Regeneration
Technical data
Compound specifications
Intermedin (Adrenomedullin-2)
- Molecular formula
- C15H25NO5 (precursor compound)
- Molecular weight
- 299.36 g/mol (precursor)
- Half-life
- Approximately 2-6 hours (varies by route of administration)
- Bioavailability
- Varies by route of administration
- CAS number
- 148498-78-6
Thymosin Beta-4
- Molecular formula
- C212H350N56O78S
- Molecular weight
- 4963
- Half-life
- Dose-dependent (increases with higher doses)
- Bioavailability
- 100% (subcutaneous and intravenous)
- CAS number
- 77591-33-4
Protocols
Dosing compared
Intermedin (Adrenomedullin-2)
No dose levels recorded.
Thymosin Beta-4
Subcutaneous injection
- 2-5 mg (community injectable practice for 'TB-500')Once or twice weekly · 4-6 week loading phase, then weekly maintenanceDocumented community/research-practice injectable dosing for tissue repair; thymosin beta-4 has ~100% bioavailability by the subcutaneous route [1]. Not an FDA-approved use.
Topical ophthalmic (eye drops)
- 0.1% (1 mg/mL) RGN-259 solution, 1 dropSeveral times daily (e.g. up to 5x/day) · 4 weeks0.1% RGN-259 ophthalmic solution used in phase III neurotrophic keratopathy and dry-eye trials, applied as eye drops several times daily for ~4 weeks [5].
Intravenous injection
- 450-1200 mgIV push daily for the first 3 days, then weekly · Total of 7 doses over ~5 weeksDoses studied in the RGN-352 acute myocardial infarction clinical program, given IV after PCI [6].
Applications
Best suited for
Intermedin (Adrenomedullin-2)
- Supporting cardiovascular health and heart function
- Intermedin (Adrenomedullin-2) is particularly well-suited for individuals focused on supporting cardiovascular health and heart function. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Managing inflammation and oxidative stress
- Intermedin (Adrenomedullin-2) is particularly well-suited for individuals focused on managing inflammation and oxidative stress. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Improving overall vascular health and circulation
- Intermedin (Adrenomedullin-2) is particularly well-suited for individuals focused on improving overall vascular health and circulation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Thymosin Beta-4
- Post-Surgery Recovery
- Accelerates healing of surgical wounds and reduces post-operative inflammation and scarring
- Chronic Wound Management
- Helps pressure ulcers, venous stasis ulcers, and other slow-healing wounds progress faster
- Tissue Regeneration
- Supports repair of damaged tissues from injury, burns, or degenerative conditions
Safety profile
Side effects
Intermedin (Adrenomedullin-2)
Common
- Mild discomfort at treatment site
- Flushing and mild facial redness
- Dizziness or lightheadedness
- Mild headache
- Injection site reactions (redness, itching, swelling)
- Nausea or mild gastrointestinal discomfort
- Fatigue or mild energy changes
- Transient hypotension (temporary low blood pressure)
- Mild palpitations (in some individuals)
Serious
- Severe allergic reaction
Thymosin Beta-4
Common
- Injection site redness
- Injection site swelling
Uncommon
- Temporary mild headache
- Mild bruising at injection site
- Transient fatigue
Serious
- Allergic reaction
Research status
Safety & evidence
Intermedin (Adrenomedullin-2)
- Evidence level
- Limited human trials
- FDA status
- Not FDA approved
- Safety overview
- Intermedin (Adrenomedullin-2) is an endogenous peptide hormone with systemic vascular and renal effects that warrant cautious use. As a vasodilator acting through CGRP and other peptide receptors, it can significantly lower blood pressure—a key safety consideration for hypotensive or cardiovascular-compromised individuals. Preclinical studies show dose-dependent hypotensive effects and tachycardia, limiting clinical translation. The compound remains largely experimental with limited safety data in humans outside specific research contexts.
Contraindications
- Pregnancy and breastfeeding - insufficient safety data
- Active cardiovascular events (heart attack, stroke)
- Severe renal (kidney) impairment
- Hypersensitivity to calcitonin family peptides
- Uncontrolled endocrine disorders
Thymosin Beta-4
- Evidence level
- Moderate human trials (Phase 1-2)
- FDA status
- Research compound
- Safety overview
- Thymosin Beta-4 is a naturally occurring peptide found in all cells and body fluids in the human body. Clinical trials have demonstrated excellent safety even at very high doses. IV studies showed doses up to 1260 mg were well tolerated with no serious adverse events.
Contraindications
- Active systemic infections
- Severe immunosuppression
- Hypersensitivity to thymosin or any component
- Pregnancy (insufficient safety data)
Decision guide
Which is right for you?
Intermedin (Adrenomedullin-2)
Choose Intermedin (Adrenomedullin-2) if…
- Supporting cardiovascular health and heart function
- Managing inflammation and oxidative stress
- Improving overall vascular health and circulation
Thymosin Beta-4
Choose Thymosin Beta-4 if…
- Recovering from injuries or surgery
- Improving wound healing speed
- Reducing inflammation
- Minimizing scar formation